The last patient visit for primary endpoint analysis has been completed in Fibrocell Science Inc.’s (FCSC) phase II trial of Azficel-T for the treatment of vocal cord scarring resulting in chronic or severe dysphonia.
Forex – financial instrument.Forex news
The last patient visit for primary endpoint analysis has been completed in Fibrocell Science Inc.’s (FCSC) phase II trial of Azficel-T for the treatment of vocal cord scarring resulting in chronic or severe dysphonia.